Back to search results

Hyperpolarized 13C-pyruvate Metabolic MRI for Glioma Diagnosis

This study is looking at a new way to diagnose brain tumors called gliomas using a special MRI scan. It uses a substance called Hyperpolarized 13C-Pyruvate (a special form of pyruvate, a natural body chemical) that helps doctors see how the tumor is using energy. The goal is to see if this special MRI can more accurately diagnose gliomas compared to standard MRI. You might be able to join if you are between 18 and 80 years old and have a suspected or confirmed glioma that requires surgery. The study aims to see if this new imaging method is safe, works well, and provides more helpful information for diagnosis.

Study design
This is an interventional study, meaning participants will receive a specific intervention. Up to 5 patients will take part in this study.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The accuracy of the metabolic MRI will be measured within three years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04772456

Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas

Recruiting
PHASE1Ages 18–80InterventionalDiagnostic
University of Maryland, Baltimore
~5 participants
Updated 2025-09-22 on ClinicalTrials.gov
What's tested:Hyperpolarized 13C-Pyruvate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Accuracy of metabolic MRI to diagnose Glioma
Measured over Within three years post treatment

Conditions

Glioma

Explore related trials

Glioma

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Dirk Mayer, Dr. rer. nat · PRINCIPAL_INVESTIGATOR · University of Maryland, Baltimore

Who to contact

Rosy Njonkou Tchoquessi
[email protected]
4107066445
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

• Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection.
Ages 18-80, including male and female
Suitable to undergo contrast-enhanced MRI
Negative serum pregnancy test

Exclusion

Inability to undergo MRI scan
Inability to receive IV contrast secondary to severe reaction or renal insufficiency.

What this trial measures

  • Accuracy of metabolic MRI to diagnose GliomaWithin three years post treatment

    To study the accuracy of hyperpolarized metabolic MRI to diagnose Glioma Cancer. We will compare the prediction of cancer from the MRI scan compared to actual diagnosis of cancer by any subsequent workup or procedure the participant undergoes. Prediction of cancer from MRI scan will be performed by assigning a standardized score . Actual diagnosis of cancer will be based on tissue pathology.